People: Adial Pharmaceuticals Inc (ADIL.OQ)

ADIL.OQ on NASDAQ Stock Exchange Capital Market

23 Nov 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Johnson, Bankole 

Dr. Bankole A. Johnson M.D. serves as Chief Medical Officer of the Company. Dr. Johnson is a world-leading neuroscientist and a pioneer in the development of medications for the treatment of alcohol abuse and is the inventor of all patents covering AD04. In August 2013, he was appointed Chairman of the Department of Psychiatry at the University of Maryland School of Medicine and also leads the Brain Science Research Consortium Unit at the University of Maryland, a position he held until March, 2019 to devote greater focus to his new duties with us. Previously, from 2004 until August 2013, he served as Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia. Dr. Johnson graduated in Medicine from Glasgow University in 1982 and trained in Psychiatry at the Royal London and Maudsley and Bethlem Royal Hospitals. Additional to his medical degree, he trained in research at the Institute of Psychiatry (University of London) and conducted studies in neuropsychopharmacology for his doctoral thesis (degree from Glasgow University) on the Medical Research Council unit at Oxford University. In 2004, Dr. Johnson earned his Doctor of Science degree in Medicine from Glasgow University — the highest degree that can be granted in science by a British university. His primary area of research expertise is the psychopharmacology of medications for treating addictions.

Basic Compensation

Total Annual Compensation, USD 271,673
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 831,575
Fiscal Year Total, USD 1,103,250

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --